These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 31744642)

  • 1. Re: Elise De Bleser, Barbara Alicja Jereczek-Fossa, David Pasquier, et al. Metastasis-directed Therapy in Treating Nodal Oligorecurrent Prostate Cancer: A Multi-institutional Analysis Comparing the Outcome and Toxicity of Stereotactic Body Radiotherapy and Elective Nodal Radiotherapy. Eur Urol 2019;76:732-9.
    Ghadjar P; Wiegel T
    Eur Urol; 2020 Mar; 77(3):e60-e61. PubMed ID: 31744642
    [No Abstract]   [Full Text] [Related]  

  • 2. Reply to Pirus Ghadjar, Thomas Wiegel's Letter to the Editor re: Elise De Bleser, Barbara Alicja Jereczek-Fossa, David Pasquier, et al. Metastasis-directed Therapy in Treating Nodal Oligorecurrent Prostate Cancer: A Multi-institutional Analysis Comparing the Outcome, Toxicity of Stereotactic Body Radiotherapy, Elective Nodal Radiotherapy. Eur Urol 2019;76:732-9.
    De Bleser E; Ost P
    Eur Urol; 2020 Mar; 77(3):e62-e63. PubMed ID: 31744645
    [No Abstract]   [Full Text] [Related]  

  • 3. Re: Metastasis-Directed Therapy in Treating Nodal Oligorecurrent Prostate Cancer: A Multi-Institutional Analysis Comparing the Outcome and Toxicity of Stereotactic Body Radiotherapy and Elective Nodal Radiotherapy.
    Taneja SS
    J Urol; 2020 Mar; 203(3):463. PubMed ID: 31829824
    [No Abstract]   [Full Text] [Related]  

  • 4. Re: Aurélie De Bruycker, Elise De Bleser, Karel Decaestecker, et al. Nodal Oligorecurrent Prostate Cancer: Anatomic Pattern of Possible Treatment Failure in Relation to Elective Surgical and Radiotherapy Treatment Templates. Eur Urol 2019;75:826-33: Nodal Recurrence of Prostate Cancer in Patients Treated with Radical Intent: Tailoring the Best Salvage Treatment.
    Montorsi F; Fossati N; Gandaglia G; Briganti A
    Eur Urol; 2020 May; 77(5):e137. PubMed ID: 32037141
    [No Abstract]   [Full Text] [Related]  

  • 5. Metastasis-directed Therapy in Treating Nodal Oligorecurrent Prostate Cancer: A Multi-institutional Analysis Comparing the Outcome and Toxicity of Stereotactic Body Radiotherapy and Elective Nodal Radiotherapy.
    De Bleser E; Jereczek-Fossa BA; Pasquier D; Zilli T; Van As N; Siva S; Fodor A; Dirix P; Gomez-Iturriaga A; Trippa F; Detti B; Ingrosso G; Triggiani L; Bruni A; Alongi F; Reynders D; De Meerleer G; Surgo A; Loukili K; Miralbell R; Silva P; Chander S; Di Muzio NG; Maranzano E; Francolini G; Lancia A; Tree A; Deantoni CL; Ponti E; Marvaso G; Goetghebeur E; Ost P
    Eur Urol; 2019 Dec; 76(6):732-739. PubMed ID: 31331782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Salvage Radiotherapy for Nodal Oligorecurrent Prostate Cancer: A Step Towards Predictive Criteria for Metastasis-Directed Therapy in Prostate Cancer?
    Desai NB; Courtney K; Subramaniam RM; Cadeddu JA
    Eur Urol; 2019 Dec; 76(6):740-742. PubMed ID: 31421942
    [No Abstract]   [Full Text] [Related]  

  • 7. Radiotherapy treatment volumes for oligorecurrent nodal prostate cancer: a systematic review.
    Achard V; Bottero M; Rouzaud M; Lancia A; Scorsetti M; Filippi AR; Franzese C; Jereczek-Fossa BA; Ingrosso G; Ost P; Zilli T
    Acta Oncol; 2020 Oct; 59(10):1224-1234. PubMed ID: 32536241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploring All Avenues for Radiotherapy in Oligorecurrent Prostate Cancer Disease Limited to Lymph Nodes: A Systematic Review of the Role of Stereotactic Body Radiotherapy.
    Ponti E; Lancia A; Ost P; Trippa F; Triggiani L; Detti B; Ingrosso G
    Eur Urol Focus; 2017 Dec; 3(6):538-544. PubMed ID: 28801240
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Re: Francolini et al.: Pattern of Recurrence After Stereotactic Radiotherapy in Prostate Cancer Patients With Nodal Pelvic Relapse. A Multi-Institutional Retrospective Analysis.
    Guler OC; Onal C
    Clin Oncol (R Coll Radiol); 2022 Jan; 34(1):e83. PubMed ID: 34838397
    [No Abstract]   [Full Text] [Related]  

  • 10. Re: David Pasquier, Thomas Lacornerie, Stéphane Supiot, et al. The Safety and Efficacy of Salvage Stereotactic Radiation Therapy in Patients with Intraprostatic Tumor Recurrence After Previous External Radiation Therapy: Phase 1 Results from the GETUG-AFU 31 Study. Eur Urol Oncol. Eur Urol Oncol. 2023;6:399-405.
    Grivas N; Zampaftis C; Ermidis D; Leotsakos I; Katafigiotis I; Karavitakis M
    Eur Urol Oncol; 2023 Dec; 6(6):640. PubMed ID: 37003860
    [No Abstract]   [Full Text] [Related]  

  • 11. Salvage reirradiation for locoregional failure after radiation therapy for prostate cancer: who, when, where and how?
    Créhange G; Roach M; Martin E; Cormier L; Peiffert D; Cochet A; Chapet O; Supiot S; Cosset JM; Bolla M; Chung HT
    Cancer Radiother; 2014 Oct; 18(5-6):524-34. PubMed ID: 25192626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: new evidence from a multicentric study.
    Triggiani L; Alongi F; Buglione M; Detti B; Santoni R; Bruni A; Maranzano E; Lohr F; D'Angelillo R; Magli A; Bonetta A; Mazzola R; Pasinetti N; Francolini G; Ingrosso G; Trippa F; Fersino S; Borghetti P; Ghirardelli P; Magrini SM
    Br J Cancer; 2017 Jun; 116(12):1520-1525. PubMed ID: 28449007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Re: Martin Spahn, Steven Joniau, Paolo Gontero, et al. Outcome predictors of radical prostatectomy in patients with prostate-specific antigen greater than 20 ng/ml: a European multi-institutional study of 712 patients. Eur Urol 2010;58:1-7.
    Neulander EZ; Wejsman Z
    Eur Urol; 2010 Sep; 58(3):e36; author reply e37-8. PubMed ID: 20605673
    [No Abstract]   [Full Text] [Related]  

  • 14. Progression-free Survival Following Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Treatment-naive Recurrence: A Multi-institutional Analysis.
    Ost P; Jereczek-Fossa BA; As NV; Zilli T; Muacevic A; Olivier K; Henderson D; Casamassima F; Orecchia R; Surgo A; Brown L; Tree A; Miralbell R; De Meerleer G
    Eur Urol; 2016 Jan; 69(1):9-12. PubMed ID: 26189689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Re: Ost P, Siva S, Brabrand S, et al. PEACE V-Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM): Acute Toxicity of a Randomized Phase 2 Trial. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2023.09.007.
    Montorsi F; Gandaglia G; Barletta F; Briganti A
    Eur Urol Oncol; 2024 Oct; 7(5):1154. PubMed ID: 38418265
    [No Abstract]   [Full Text] [Related]  

  • 16. High-dose-rate stereotactic body radiation therapy for postradiation therapy locally recurrent prostatic carcinoma: Preliminary prostate-specific antigen response, disease-free survival, and toxicity assessment.
    Fuller DB; Wurzer J; Shirazi R; Bridge SS; Law J; Mardirossian G
    Pract Radiat Oncol; 2015; 5(6):e615-23. PubMed ID: 26059509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Re: Giorgio Gandaglia, Stephen A. Boorjian, William P. Parker, et al. Impact of Postoperative Radiotherapy in Men with Persistently Elevated Prostate-specific Antigen After Radical Prostatectomy for Prostate Cancer: A Long-term Survival Analysis. Eur Urol 2017;72:910-7.
    Dal Pra A; Supiot S; Ghadjar P
    Eur Urol; 2018 Feb; 73(2):e34-e35. PubMed ID: 28890243
    [No Abstract]   [Full Text] [Related]  

  • 18. Re: Giorgio Gandaglia, Stephen A. Boorjian, William P. Parker, et al. Impact of Postoperative Radiotherapy in Men with Persistently Elevated Prostate-specific Antigen After Radical Prostatectomy for Prostate Cancer: A Long-term Survival Analysis. Eur Urol 2017;72:910-7.
    Temiz MZ; Besiroglu H
    Eur Urol; 2018 May; 73(5):e130. PubMed ID: 29397220
    [No Abstract]   [Full Text] [Related]  

  • 19. Re: Brandon A. Mahal, David D. Yang, Natalie Q. Wang, et al. Clinical and Genomic Characterization of Low-Prostate-specific Antigen, High-grade Prostate Cancer. Eur Urol 2018;74:146-54.
    Leppert JT; Brooks JD
    Eur Urol; 2018 Nov; 74(5):e110-e111. PubMed ID: 30017399
    [No Abstract]   [Full Text] [Related]  

  • 20. Pattern of Progression after Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Nodal Recurrences.
    Ost P; Jereczek-Fossa BA; Van As N; Zilli T; Tree A; Henderson D; Orecchia R; Casamassima F; Surgo A; Miralbell R; De Meerleer G
    Clin Oncol (R Coll Radiol); 2016 Sep; 28(9):e115-20. PubMed ID: 27133946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.